Squarepoint
QNCX icon

Squarepoint’s Quince Therapeutics QNCX Stock Holding History

Squarepoint’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-205
Closed -$91K – 3350
2022
Q2 		$91K Buy
205
+147
+253% +$104K ﹤0.01% 2633
2022
Q1 		$72K Sell
58
-667
-92% -$908K ﹤0.01% 2648
2021
Q4 		$1.83M Buy
725
+679
+1,476% +$4.14M ﹤0.01% 1309
2021
Q3 		$838K Buy
+46
New +$732K ﹤0.01% 1669
2021
Q2 		– Sell
-42
Closed -$301K – 3609
2021
Q1 		$301K Sell
42
-160
-79% -$1.15M ﹤0.01% 2391
2020
Q4 		$1.12M Buy
202
+160
+381% +$1.42M 0.01% 1258
2020
Q3 		$417K Sell
42
-33
-44% -$300K 0.01% 1563
2020
Q2 		$699K Buy
75
+29
+63% +$266K 0.01% 1132
2020
Q1 		$423K Buy
+46
New +$454K 0.01% 1128

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

Squarepoint's QNCX Position: Q3 2022 in Review

Squarepoint sold out of Quince Therapeutics (QNCX) in Q3 2022, closing a stake of 205 shares — an estimated $91K sold.

Squarepoint first reported a position in QNCX in Q1 2020 and held it in 9 quarters. The position peaked at $1.83M in Q4 2021. 58 funds tracked by Wall St. Rank hold QNCX as of Q3 2022.

  • Squarepoint reported no remaining Quince Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Squarepoint sold 205 Quince Therapeutics shares in Q3 2022, an estimated $91K.
  • Squarepoint first reported a position in Quince Therapeutics in Q1 2020 and held it in 9 quarters.
  • Squarepoint's Quince Therapeutics position peaked at $1.83M in Q4 2021.
  • 58 funds tracked by Wall St. Rank held Quince Therapeutics as of Q3 2022.

Based on Squarepoint's 13F filing for Q3 2022, filed 14 Nov 2022.